Navigation Links
EndoChoice(R) Receives 510K Clearance for its BONASTENT(R) Esophageal and Biliary Stent Platforms
Date:4/29/2010

ALPHARETTA, Ga., April 29 /PRNewswire/ -- EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

With over 8,000 placements worldwide, the BONASTENT platform has provided physicians treating malignant strictures in the GI tract increased clinical performance attributed to its revolutionary "Hook & Cross" wire geometry. The BONASTENT's proprietary Hook & Cross wire geometry provides segmental compression, reducing stent migration typically experienced with other metal stent platforms.  

"I have been very pleased with my placements of the BONASTENT," said Peter Stevens, M.D., Director of Endoscopy at New York Presbyterian Hospital/Columbia University Medical Center in New York. "It has performed beautifully and I look forward to incorporating future EndoChoice BONASTENT platforms into my practice."

"This revolutionary line of metal stents will make a tremendous impact improving the quality of life for the tens of thousands of patients suffering from GI cancers," said Mark Gilreath, Founder and CEO of EndoChoice.  "We are pleased to have such a successful product launch in the United States and Europe.  Patients can now benefit from the unique feature of segmental compression, only offered in the BONASTENT platform technology."

The BONASTENT platform will be available for hands-on demonstration at the 2010 Digestive Disease Week conference, which is being held in New Orleans on May 2nd through 5th.

BONASTENT Esophageal

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100429/NY95943 )

About EndoChoice, Inc.

EndoChoice designs, manufactures and markets innovative solutions for professionals in gastrointestinal endoscopy worldwide.  Its diverse portfolio of high-quality equipment, devices, supplies and services uniquely positions EndoChoice as a leading resource for GI professionals.  The company strives to exceed its customers' expectations through its superior products, exemplary customer care, knowledgeable sales force, and easy online ordering.  For more information, visit www.EndoChoice.com.


'/>"/>
SOURCE EndoChoice, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products
2. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
3. Mylan Receives Approval for Generic Version of Flomax(R)
4. BioMedix Receives Clinical Approval for TRAKnet Software
5. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
6. Flexuspine Receives FDA Conditional Approval to Begin a Feasibility Study of Its FSU (Functional Spinal Unit) Total Spine Arthroplasty System in the United States
7. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
8. ATS Medical Receives Approval to Commercialize the ATS Simulus Annuloplasty Products in Canada
9. Actavis Receives Approval of Alprazolam ODT in the U.S.
10. Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
11. Watson Receives FDA Approval for Generic Cardizem(R) LA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
(Date:12/8/2016)... , Dec. 8, 2016 Allergy ... includes products and tests that are used to ... weed, peanuts, milk, or drugs etc. in the ... by the immune system. The report on global ... prospects of the market. The report consists of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
Breaking Medicine News(10 mins):